Key result
Nonelutable LMWH stent coating cuts in-vitro platelet deposition ~95% vs uncoated controls.
Why the study?
Low-molecular weight heparin is widely used during PCI but a nonelutable LMWH stent coating for enhanced thromboresistance has not been developed.
Does a nonelutable low-molecular weight heparin stent coating improve thromboresistance compared to uncoated stents in an in-vitro model?
Does a nonelutable low-molecular weight heparin stent coating improve thromboresistance compared to uncoated stents in an in-vitro model?
Effect estimate: 95% reduction
A novel nonelutable LMWH coating on sirolimus-eluting stents significantly reduces platelet deposition in vitro, suggesting potential for reducing stent thrombosis risk.
No takes yet. Share an insight, caveat, or question.
Supports development of thromboresistant stent coatings; leaves open in-vivo and clinical validation.
Zhao et al. (2012) studied this question. Nonelutable low-molecular weight heparin (LMWH) stent coating vs. Uncoated control stents was evaluated on Platelet deposition in an in-vitro bovine blood flow loop (95% reduction). A nonelutable low-molecular weight heparin stent coating demonstrated a 95% reduction in platelet deposition compared to uncoated control stents in an in-vitro bovine blood flow loop.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: